Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Ångstrom Pharmaceuticals
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Females ≥18 years of age
Histologically or cytologically documented primary epithelial ovarian carcinoma, cancer of the Fallopian tube, or primary peritoneal carcinoma
Completion of first-line chemotherapy
Clinical remission as a result of chemotherapy
History of normal CA125 level after initial course of therapy
CA125 serum level has shown 2 consecutive rises based on 3 consecutive samples which are mutually \>= 28 days apart, provided that:
1. the 3rd sample is above the institution's ULN, and
2. the 3rd sample is confirmed by a 4th sample which is likewise higher than the 2nd sample value and is above the institution's ULN
No clinically evident disease progression, as assessed by history, physical examination, computed tomographic (CT) scan, or magnetic resonance imaging (MRI)
ECOG Performance Status of 0 or 1
No clinically significantly abnormal clinical laboratory tests or concomitant illnesses
Ability and willingness to self-administer subcutaneous injections
Although pregnancy is extremely unlikely in this patient population because of the disease and prior treatment, patients who have the potential to become pregnant must have a negative pregnancy test and must agree to practice an effective method of contraception throughout the trial.
You may not be if
Persistent adverse events due to agents administered more than 4 weeks earlier
More than 1 course of previous chemotherapy for the qualifying cancer
Disease requiring chemotherapy or radiotherapy
Ascites
Recent history of active infection, gastrointestinal bleeding, thromboembolic disorders, or anticoagulation
Clareo Health | Efficacy of Å6 in Ovarian Cancer Patients Following First-Line Chemotherapy and a Rising CA125 Levels
